Antibody Targeting of Eph Receptors in Cancer

Janes, Peter W.; Vail, Mary E.; Gan, Hui; Scott, Andrew

doi:10.3390/ph13050088

Cited by 32 publications

(22 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Eph receptors are the largest family of RTKs, with 14 receptors divided into EphA and EphB subcategories, which bind to different types of ephrin ligands [ 329 ]. Eph/ephrin expression, clinical outcome and function in GB has been reviewed, including the use of Eph receptors as therapeutic targets [ 62 , 330 , 331 ].…”

Section: Receptor Tyrosine Kinase Inhibitors (Rtkis) For Gb Therapymentioning

confidence: 99%

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

et al. 2021

View full text Add to dashboard Cite

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

show abstract

Section: Receptor Tyrosine Kinase Inhibitors (Rtkis) For Gb Therapymentioning

confidence: 99%

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite many difficulties, more and more centers are conducting research on the possibility of using drugs that affect the Eph and ephrin signaling pathways [24,93,94]. Over time, there should be more evidence of their safety, also for the retina and other eye tissues.…”

Section: Safety Of the Use Of Drugs Acting On Eph In The Eyesmentioning

confidence: 99%

Eph Receptors and Ephrins in Retinal Diseases

Kaczmarek

Gajdzis

2021

IJMS

View full text Add to dashboard Cite

Retinal diseases are the leading cause of irreversible blindness. They affect people of all ages, from newborns in retinopathy of prematurity, through age-independent diabetic retinopathy and complications of retinal detachment, to age-related macular degeneration (AMD), which occurs mainly in the elderly. Generally speaking, the causes of all problems are disturbances in blood supply, hypoxia, the formation of abnormal blood vessels, and fibrosis. Although the detailed mechanisms underlying them are varied, the common point is the involvement of Eph receptors and ephrins in their pathogenesis. In our study, we briefly discussed the pathophysiology of the most common retinal diseases (diabetic retinopathy, retinopathy of prematurity, proliferative vitreoretinopathy, and choroidal neovascularization) and collected available research results on the role of Eph and ephrins. We also discussed the safety aspect of the use of drugs acting on Eph and ephrin for ophthalmic indications.

show abstract

“…More and more studies are available on drugs modifying the action of Eph and ephrins [ 63 , 64 ]. Much attention is paid to the role of monoclonal antibodies targeting Eph receptors, due to their relatively high target specificity [ 65 , 66 ]. Of course, the exact safety profile of Eph inhibitors still requires intensive research.…”

Section: Possible Applications Of Eph and Ephrin Signaling System Modifying Drugs In Corneal Diseasesmentioning

confidence: 99%

The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases

Kaczmarek

Zimmer

Gajdzis

et al. 2021

IJMS

View full text Add to dashboard Cite

The cornea, while appearing to be simple tissue, is actually an extremely complex structure. In order for it to retain its biomechanical and optical properties, perfect organization of its cells is essential. Proper regeneration is especially important after injuries and in the course of various diseases. Eph receptors and ephrin are mainly responsible for the proper organization of tissues as well as cell migration and communication. In this review, we present the current state of knowledge on the role of Eph and ephrins in corneal physiology and diseases, in particular, we focused on the functions of the epithelium and endothelium. Since the role of Eph and ephrins in the angiogenesis process has been well established, we also analyzed their influence on conditions with corneal neovascularization.

show abstract

Antibody Targeting of Eph Receptors in Cancer

Cited by 32 publications

References 74 publications

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

Eph Receptors and Ephrins in Retinal Diseases

The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases

Contact Info

Product

Resources

About